Bristol Myers Squibb (CELG-RI) EBT Margin (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported EBT Margin for 18 consecutive years, with 31.5% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT Margin rose 1705.0% year-over-year to 31.5% in Q2 2026; TTM through Jun 2026 was 24.21%, a 1039.0% increase from a year earlier, with the FY2025 full-year figure at 19.36%, up 3670.0% from the prior year.
• EBT Margin was 31.5% for Q2 2026 at Bristol Myers Squibb, up from 28.2% in the prior quarter.
• Over five years, EBT Margin peaked at 31.5% in Q2 2026 and troughed at 97.06% in Q1 2024.
• A 5-year average of 11.61% and a median of 16.39% in 2022 frame the typical range for EBT Margin.
• Across the five-year window, EBT Margin slumped 12149 bps in 2024 and surged 12358 bps in 2025, its largest moves.
• Over 5 years, EBT Margin stood at 16.3% in 2022, then decreased by 11 bps to 14.59% in 2023, then tumbled by 90 bps to 1.42% in 2024, then surged by 729 bps to 11.76% in 2025, then surged by 168 bps to 31.5% in 2026.
• The last three EBT Margin figures came in at 31.5% (Q2 2026), 28.2% (Q1 2026), and 11.76% (Q4 2025), per Business Quant data.